Vanguard CPV, ενέσιμο διάλυμα για σκύλους
Vanguard CPV, ενέσιμο διάλυμα για σκύλους
Authorised
- Canine parvovirus, strain NL-35-D, Live
Product identification
Medicine name:
Vanguard CPV, ενέσιμο διάλυμα για σκύλους
Active substance:
- Canine parvovirus, strain NL-35-D, Live
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Canine parvovirus, strain NL-35-D, Live7.00/log10 unit(s)1.0050% tissue culture infectious dose/dose
Pharmaceutical form:
-
Solution for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AI05
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Cyprus
Available in:
-
Cyprus
Package description:
- Available only in Greek
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Zoetis Hellas S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
- Zoetis Belgium
Responsible authority:
- Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment
Authorisation number:
- 16339
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Greek (PDF)
Published on: 31/08/2022
